MYC: A Stratification Marker for Pancreatic Cancer Therapy

Overview

Journal Trends Cancer

Publisher Cell Press

Specialty Oncology

Date 2017 Jul 26

PMID 28741497

Citations 14

Authors

Matthias Wirth

Gunter Schneider

Affiliations

Soon will be listed here.

Abstract

One approach to improve cancer treatment is to stratify patients and to develop subgroup-specific therapies. We will discuss the potential of MYC as a stratification marker in pancreatic ductal adenocarcinoma. Furthermore, we will point to possibilities for how to annotate the MYC status and how to target MYC-associated vulnerabilities.

Citing Articles

The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma.

Blazquez-Encinas R, Alors-Perez E, Moreno-Montilla M, Garcia-Vioque V, Sanchez-Frias M, Mafficini A Cancer Gene Ther. 2024; 31(11):1646-1657.

PMID: 39232176 PMC: 11567885. DOI: 10.1038/s41417-024-00814-3.

Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer.

Wan L, Lin K, Rahman M, Ishigami Y, Wang Z, Jensen M Cancer Discov. 2023; 13(7):1678-1695.

PMID: 37098965 PMC: 10330071. DOI: 10.1158/2159-8290.CD-22-1013.

Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.

Orben F, Lankes K, Schneeweis C, Hassan Z, Jakubowsky H, Krauss L JCI Insight. 2022; 7(10).

PMID: 35439169 PMC: 9220834. DOI: 10.1172/jci.insight.151353.

Alantolactone: A Natural Plant Extract as a Potential Therapeutic Agent for Cancer.

Cai Y, Gao K, Peng B, Xu Z, Peng J, Li J Front Pharmacol. 2021; 12:781033.

PMID: 34899346 PMC: 8664235. DOI: 10.3389/fphar.2021.781033.

Rationale for MYC imaging and targeting in pancreatic cancer.

Schneider G, Wirth M, Keller U, Saur D EJNMMI Res. 2021; 11(1):104.

PMID: 34637026 PMC: 8511206. DOI: 10.1186/s13550-021-00843-1.